company background image
MYX logo

Mayne Pharma Group ASX:MYX Stock Report

Last Price

AU$4.61

Market Cap

AU$378.1m

7D

-0.9%

1Y

17.0%

Updated

21 Jun, 2024

Data

Company Financials +

Mayne Pharma Group Limited

ASX:MYX Stock Report

Market Cap: AU$378.1m

MYX Stock Overview

A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

MYX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Mayne Pharma Group Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mayne Pharma Group
Historical stock prices
Current Share PriceAU$4.61
52 Week HighAU$7.46
52 Week LowAU$2.75
Beta1.21
11 Month Change-13.67%
3 Month Change-33.76%
1 Year Change17.01%
33 Year Change-31.19%
5 Year Change-54.80%
Change since IPO-61.58%

Recent News & Updates

Recent updates

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Dec 03
Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Dec 01
Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Apr 12
Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16
We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10
Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17
Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22
Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01
How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08
What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18
Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27
Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09
Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24
A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Shareholder Returns

MYXAU PharmaceuticalsAU Market
7D-0.9%-0.9%0.1%
1Y17.0%63.7%8.5%

Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned 63.7% over the past year.

Return vs Market: MYX exceeded the Australian Market which returned 8.5% over the past year.

Price Volatility

Is MYX's price volatile compared to industry and market?
MYX volatility
MYX Average Weekly Movement6.6%
Pharmaceuticals Industry Average Movement9.8%
Market Average Movement8.4%
10% most volatile stocks in AU Market16.2%
10% least volatile stocks in AU Market3.2%

Stable Share Price: MYX's share price has been volatile over the past 3 months.

Volatility Over Time: MYX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005n/aShawn O’Brienwww.maynepharma.com

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.

Mayne Pharma Group Limited Fundamentals Summary

How do Mayne Pharma Group's earnings and revenue compare to its market cap?
MYX fundamental statistics
Market capAU$378.15m
Earnings (TTM)-AU$274.18m
Revenue (TTM)AU$319.28m

1.2x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MYX income statement (TTM)
RevenueAU$319.28m
Cost of RevenueAU$145.07m
Gross ProfitAU$174.21m
Other ExpensesAU$448.39m
Earnings-AU$274.18m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 23, 2024

Earnings per share (EPS)-3.38
Gross Margin54.56%
Net Profit Margin-85.87%
Debt/Equity Ratio5.5%

How did MYX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.